Literature DB >> 63748

Differential response of chlamydial and ureaplasma-associated urethritis to sulphafurazole (sulfisoxazole) and aminocyclitols.

W R Bowie, J F Floyd, Y Miller, E R Alexander, J Holmes, K K Holmes.   

Abstract

91 men with n class="Disease">non-gonococcal urethritis (N.G.U.) were randomly treated with either sulphafurazole (sulfisoxazole), 500 mg orally q.i.d. for 10 days, or an aminocyclitol (streptomycin or spectinomycin), 2 g intramuscularity for 1 to 3 doses at 12 h intervals. Initial urethral cultures were positive for Chlamydia trachomatis (C) in 36 (40%). Ureaplasma urealyticum (U) was isolated from the urethra or urine from20 (95%) of 21 White men in a first episode of N.G.U. who had negative chlamydia cultures. Sulphafurazole, active against C. trachomatis but not U. urealyticum in vitro, produced a clinical response in 7 of 7 men with C+U- N.G.U. and 5 of 19 with C-U+ N.G.U. (P less than 0-01). Aminocyclitols, active against U. urealyticum but relatively inactive against C. trachomatis in vitro produced a clinical response in 0 of 6 men with C+U-N.G.U., 9 of 11 men with C-U+N.G.U. from whom ureaplasma was eradicated (P less than 0-01), and 0 of 8 with C-U+ N.G.U. from whom ureaplasma was not eradicated. C+U+ N.G.U. responded poorly to both antimicrobials alone. These results support the aetiological importance of both C. trachomatis and U. urealyticum in N.G.U.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 63748     DOI: 10.1016/s0140-6736(76)92034-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

Review 1.  Nongonococcal urethritis: diagnosis and management.

Authors:  L M Lucas; D L Smith
Journal:  J Gen Intern Med       Date:  1987 May-Jun       Impact factor: 5.128

2.  Diagnostic, treatment, and reporting criteria for non-specific genital infection in sexually transmitted disease clinics in England and Wales. 1: Diagnosis.

Authors:  M W Adler
Journal:  Br J Vener Dis       Date:  1978-12

Review 3.  Drug therapies for sexually transmitted diseases. Clinical and economic considerations.

Authors:  W R Bowie
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

4.  Serological characterisation of Ureaplasma urealyticum strains by enzyme-linked immunosorbent assay (ELISA).

Authors:  H Turunen; P Leinikki; E Jansson
Journal:  J Clin Pathol       Date:  1982-04       Impact factor: 3.411

Review 5.  The rôle of Chlamydia trachomatis in genital-tract and associated diseases.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  J Clin Pathol       Date:  1980-03       Impact factor: 3.411

6.  Genitourinary infection with Ureaplasma urealyticum in women attending a sexually transmitted diseases clinic.

Authors:  J M Hunter; H Young; A B Harris
Journal:  Br J Vener Dis       Date:  1981-10

7.  Antimicrobial susceptibility of Ureaplasma urealyticum.

Authors:  J W Davis; B A Hanna
Journal:  J Clin Microbiol       Date:  1981-02       Impact factor: 5.948

8.  Lack of in vitro activity of cefoxitin, cefamandole, cefuroxime, and piperacillin against Chlamydia trachomatis.

Authors:  W R Bowie
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

9.  Treatment of nongonococcal urethritis with rifampicin as a means of defining the role of Ureaplasma urealyticum.

Authors:  E D Coufalik; D Taylor-Robinson; G W Csonka
Journal:  Br J Vener Dis       Date:  1979-02

10.  In vitro and in vivo efficacy of antimicrobials against Chlamydia trachomatis.

Authors:  W R Bowie
Journal:  Infection       Date:  1982       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.